Summary
A series of phase II studies using ifosfamide (IFX) as a single agent and in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer have been coordinated at the West Midlands CRC Clinical Trials Unit (Birmingham, UK). The aims of these studies were to identify single agents and combination regimens that may be of value for palliation and have potential for use as neoadjuvant and adjuvant therapy at the time of primary treatment. A total of 79 patients with disease non-amenable to radical local therapy were treated with single-agent IFX or the BIP combination. In 30 patients treated with single-agent IFX, 10 objective responses (30%) were seen, with 1 complete response. In 49 patients treated with BIP, 34 objective responses (69%) were seen, with 10 complete responses (20%). Toxicity included alopecia, nausea and vomiting, myelosuppression, infection, reduction in renal function and disturbance of consciousness. These data indicate that IFX is highly active in cervix cancer and, in combination with bleomycin and cisplatin, can be used for effective palliation and cytoreduction in >70% of patients. IFX-containing regimens have potential for use as neoadjuvant and adjuvant therapy in patients at high risk of recurrence with conventional treatment. These hypotheses are currently being tested in prospective randomised trials.
Similar content being viewed by others
References
Bonomi P, Bruckner H, Cohen C, Marshall R, Blessing J, Slayton R (1982) A randomized trial of three cisplatin regimens in squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 18: 110
Coleman R, Harper P, Gallagher M, Osborne R, Rankin E, Silverstone A, Slevin M, Souhami R, Tobias J, Trask C, Wiltshaw E (1986) A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 18: 280–283
De Palo G (1977) Medical treatment of advanced carcinoma of the cervix. A review. Tumori 63: 215–235
De Vita V, Wasserman T, Young R, Carter S (1976) Perspective on research in gynaecologic oncology. Cancer 38: 509–525
Di Saia P, Rich W (1975) Advanced and recurrent carcinoma of cervix. Gynecol Oncol: 517–527
Dixon W, Brown M, Engelman L, Frane J, Hill M, Jennrich R, Toporek J (1985) BMDP statistical software manual, 5th edn. University of California. Berkeley
Friedlander M, Kaye S, Sullivan A, Green D, Houghton R, Solomon H, Russell, Tattersall M (1983) Cervival carcinoma: a drug-responsive tumour-experience with combined cisplatin, vinblastine and bleomycin therapy. Gynecol Oncol 16: 275–281
Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 9: 14–23
Hilgard P, Herdrich K, Brade W (1983) Ifosfamide-current aspects and perspectives. Cancer Treat Rev 10: 183–192
Hunter H, Harrison E (1982) The anticancer spectrum of ifosfamide. Semin Oncol 9: 96–100
Meanwell C, Blake E, Kelly K, Honigsberger L, Blackledge G, (1986) Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 22: 815–819
Meanwell C, Mould J, Blackledge G, Lawton F, Stuart N, Kavanagh J, Latief T, Spooner D, Chetiyawardana A (1986) Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep 70: 727–730
Meanwell C, Kelly K, Wilson S, Roginski C, Woodman C, Griffiths R, Blackledge G (1988) Young age as a prognostic factor in cervical cancer: analysis of population based data from 10022 cases. Br Med J 296: 386–391
Miller A, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
OPCS (1988) Cancer statistics and registrations. HMSO, London
Vermorken J, Mangioni C, Oosterom A van, Pecorelli C, Burg M van den, Ten Bokkel Huinink W, Dalesio O, Rotmenmsz N (1983) Vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in squamous cell carcinoma of the uterine cervix (SCCUC). In: Proceedings of the 2nd European Conference on Clinical Oncology. p 50
Wasserman T, Comis R, Goldsmith M, Handelsman H, Penta J, Slavik M, Soper W, Carter S (1975) Tabular analysis of the clinical therapy of solid tumours. Cancer Treat Rep 6: 399–419
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blackledge, G., Buxton, E.J., Mould, J.J. et al. Phase II studies of ifosfamide alone and in combination in cancer of the cervix. Cancer Chemother. Pharmacol. 26 (Suppl 1), S12–S16 (1990). https://doi.org/10.1007/BF00685409
Issue Date:
DOI: https://doi.org/10.1007/BF00685409